Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Advances in Liposomes for Drug Delivery
share announcement

Advances in Liposomes for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 2409

Special Issue Editors

Prof. Dr. Sophia G. Antimisiaris

E-Mail Website
Guest Editor
1. Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Rio-Patras, Greece
2. Institute for Chemical Engineering Sciences, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Stadiou Street, 26510 Platani-Rio, Greece
Interests: targeted drug delivery; nanomedicines; liposome technology; lipid-based formulations
Special Issues, Collections and Topics in MDPI journals
Dr. Athanasios Skouras

E-Mail Website
Guest Editor
Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Heraklion, 71004 Crete, Greece
Interests: liposomes; nanoparticles; hydrogels; 2D nanomaterials; biopolymers
Special Issues, Collections and Topics in MDPI journals
Dr. Antonia Marazioti

E-Mail Website
Guest Editor
Laboratory of Basic Sciences, Department of Physiotherapy, School of Health Sciences, University of Peloponnese, Efstathiou & Stamatikis Valioti and Plataion, 23100 Sparta, Greece
Interests: targeted drug delivery; tumor biology; liposomes and bioinspired nanocarriers; local drug delivery systems

Special Issue Information

Dear Colleagues,

Liposomes are small spherical vesicular structures composed of one or more phospholipid bilayers. Liposomal drug delivery systems possess specific features, including nano size, biodegradability, hydrophobic/hydrophilic characteristics, biocompatibility, and low or no toxicity and immunogenicity, which can all lead to considerable efficacy in treating various types of diseases. The rationale for developing liposomal-based drug delivery systems is to improve the therapeutic efficacy of drugs by reducing drug toxicity, improving drug solubility and stability, enhancing drug delivery to specific targets, and/or increasing their permeation across biological barriers. The diverse applications of liposomes as carriers for the delivery of drugs and other molecules have been attributed to the physicochemical and biophysical characteristics of the liposomal membrane and especially of the vesicle surface.

This Special Issue welcomes studies that include (but are not limited to) all aspects of liposomal drug delivery systems including their design, development, and characterizations as well as their pharmacodynamic and pharmacokinetic properties and their use as strategies for the prevention or treatment of medical conditions such as cancer, infection, inflammation, oxidant-induced tissue injuries, dermatological diseases, etc. Original research articles and comprehensive reviews are especially welcome.

Prof. Dr. Sophia G. Antimisiaris
Dr. Athanasios Skouras
Dr. Antonia Marazioti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liposomes
  • drug delivery
  • liposome-based therapeutics
  • controlled release
  • liposome technology
  • encapsulation
  • liposome stability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 4395 KiB  
Article
In Vitro and In Vivo Evaluation of Lactoferrin-Modified Liposomal Etomidate with Enhanced Brain-Targeting Effect for General Anesthesia
by Ailing Wu, Houyin Shi, Luhan Yang, Hao Zhang, Xichen Nan, Dan Zhang, Zhuo Zhang, Chun Zhang, Siwei Chen, Xiujuan Fu, Lilan Ou, Lulu Wang, Yanyan Shi and Hao Liu
Pharmaceutics 2024, 16(6), 805; https://doi.org/10.3390/pharmaceutics16060805 - 14 Jun 2024
Viewed by 842
Abstract
Etomidate is a general anesthetic that has shown good hemodynamic stability without significant cardiovascular or respiratory depression. Despite several kinds of dosage forms having been reported for this drug, formulation types are very limited in clinical practice, and brain-targeted formulations for this central [...] Read more.
Etomidate is a general anesthetic that has shown good hemodynamic stability without significant cardiovascular or respiratory depression. Despite several kinds of dosage forms having been reported for this drug, formulation types are very limited in clinical practice, and brain-targeted formulations for this central nervous system (CNS) drug have been rarely reported. Moreover, studies on the biocompatibility, toxicity, and anesthetic effects of the etomidate preparations in vivo were inadequate. The present study was to develop lactoferrin-modified liposomal etomidate (Eto-lip-LF) for enhanced drug distribution in the brain and improved anesthetic effects. Eto-lip-LF had good stability for storage and hemocompatibility for intravenous injection. Compared with the non-lactoferrin-containing liposomes, the lactoferrin-modified liposomes had notably enhanced brain-targeting ability in vivo, which was probably realized by the binding of transferrin with the transferrin and lactoferrin receptors highly distributed in the brain. Eto-lip-LF had a therapeutic index of about 25.3, higher than that of many other general anesthetics. Moreover, compared with the commercial etomidate emulsion, Eto-lip-LF could better achieve rapid onset of general anesthesia and rapid recovery from anesthesia, probably due to the enhanced drug delivery to the brain. The above results demonstrated the potential of this lactoferrin-modified liposomal etomidate to become an alternative preparation for clinical general anesthesia. Full article
(This article belongs to the Special Issue Advances in Liposomes for Drug Delivery)
►▼ Show Figures

Graphical abstract

21 pages, 3903 KiB  
Article
Daptomycin Liposomes Exhibit Enhanced Activity against Staphylococci Biofilms Compared to Free Drug
by Foteini Gkartziou, Maria Plota, Charikleia Kypraiou, Iti Gauttam, Fevronia Kolonitsiou, Pavlos Klepetsanis, Iris Spiliopoulou and Sophia G. Antimisiaris
Pharmaceutics 2024, 16(4), 459; https://doi.org/10.3390/pharmaceutics16040459 - 26 Mar 2024
Viewed by 1165
Abstract
The purpose of the present study was to investigate the anti-staphylococcal activity of liposomal daptomycin against four biofilm-producing S. aureus and S. epidermidis clinical strains, three of which are methicillin-resistant. Neutral and negatively charged daptomycin-loaded liposomes were prepared using three methods, namely, thin-film [...] Read more.
The purpose of the present study was to investigate the anti-staphylococcal activity of liposomal daptomycin against four biofilm-producing S. aureus and S. epidermidis clinical strains, three of which are methicillin-resistant. Neutral and negatively charged daptomycin-loaded liposomes were prepared using three methods, namely, thin-film hydration (TFH), a dehydration–rehydration vesicle (DRV) method, and microfluidic mixing (MM); moreover, they were characterized for drug encapsulation (EE%), size distribution, zeta-potential, vesicle stability, drug release, and drug integrity. Interestingly, whilst drug loading in THF and DRV nanosized (by extrusion) vesicles was around 30–35, very low loading (~4%) was possible in MM vesicles, requiring further explanatory investigations. Liposomal encapsulation protected daptomycin from degradation and preserved its bioactivity. Biofilm mass (crystal violet, CV), biofilm viability (MTT), and growth curve (GC) assays evaluated the antimicrobial activity of neutral and negatively charged daptomycin-liposomes towards planktonic bacteria and biofilms. Neutral liposomes exhibited dramatically enhanced inhibition of bacterial growth (compared to the free drug) for all species studied, while negatively charged liposomes were totally inactive. Biofilm prevention and treatment studies revealed high antibiofilm activity of liposomal daptomycin. Neutral liposomes were more active for prevention and negative charge ones for treating established biofilms. Planktonic bacteria as well as the matured biofilms of low daptomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE) strains were almost completely eradicated by liposomal-daptomycin, indicating the need for their further exploration as antimicrobial therapeutics. Full article
(This article belongs to the Special Issue Advances in Liposomes for Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop